Whalesbook
So, jab Chemkart India ne apne audited FY26 financials release kiye, toh market ki nazar numbers par thi. Company ne revenue toh manage kar liya, woh ₹215.49 Crore tak pahunch gaya, jo pichle saal se 5% zyada hai. Lekin bhai, andar ki kahani kuch aur hi hai. Profit Before Tax (PBT) mein toh 60% ka bada fall aaya, ₹32.47 Crore se seedha ₹13.08 Crore par aa gaya. Iska seedha impact pada PAT par, jo 61% ghata aur ₹9.51 Crore par aa gaya, jo FY25 mein ₹24.51 Crore tha. Matlab, jab revenue badh raha tha, profit kharab ho gaya!
Ab is profit ki kami ka ek bada reason hai pending customs litigation. Company ne is case ke liye ₹14.74 Crore ka payment kiya hai. Management bol rahi hai ki ye paisa recover ho jayega, par cash toh abhi outflow ho gaya na? Isliye profit par pressure aaya. Achhi baat ye hai ki auditors ne financials ko 'unmodified opinion' diya hai, matlab unhein koi badi gadbad nahi dikhi.
Aur haan, IPO se jo paise aaye the, usmein se ₹4.61 Crore facility pe kharche hue, ₹20 Crore loan chukane mein gaye, aur lagbhag ₹28.00 Crore toh abhi bhi liquid funds mein safe rakhe hue hain, March 2026 tak ke data ke according.
Ye results isliye important hain kyunki revenue grow hone ke baad bhi profit itna girna company ke operational efficiency aur cost management par sawal khada karta hai. Aur ye customs litigation wala risk bhi investors ko thoda pareshan kar sakta hai, jab tak recoverability clear na ho jaye.
Agar hum is sector ke competitors, jaise Neogen Chemicals ya Tatva Chintan Pharma Chem ko dekhein, toh unka profit growth kaafi stable raha hai recently. Chemkart India ka ye picture thoda alag aur chinta janak lag raha hai, jo suggest karta hai ki company ko shayad internal issues par zyada dhyan dena hoga.
Ab investors ko ye dekhna hai ki management is profit fall aur cost issues par kya explanation deta hai. Customs litigation ka update aur recovery status bohot crucial rahega. Aur FY27 mein company apne margins kaise improve karti hai, ye bhi track karna hoga.